Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study

Open access
Tammemägi, Martin C, Ruparel, Mamta, Tremblay, Alain, Myers, Renelle, Mayo, John, Yee, John, Atkar-Khattra, Sukhinder, Yuan, Ren, Cressman, Sonya, English, John, Bedard, Eric, MacEachern, Paul, Burrowes, Paul, Quaife, Samantha L, Marshall, Henry, Yang, Ian, Bowman, Rayleen, Passmore, Linda, McWilliams, Annette, Brims, Fraser, Lim, Kuan Pin, Mo, Lin, Melsom, Stephen, Saffar, Bann, Teh, Mark, Sheehan, Ramon, Kuok, Yijin, Manser, Renee, Irving, Louis, Steinfort, Daniel, McCusker, Mark, Pascoe, Diane, Fogarty, Paul, Stone, Emily, Lam, David C L, Ng, Ming-Yen, Vardhanabhuti, Varut, Berg, Christine D, Hung, Rayjean J, Janes, Samuel M, Fong, Kwun, Lam, Stephen · 2022 · The Lancet Oncology

Abstract

BACKGROUND: Lung cancer is a major health problem. CT lung screening can reduce lung cancer mortality through early diagnosis by at least 20%. Screening high-risk individuals is most effective. Retrospective analyses suggest that identifying individuals for screening by accurate prediction models is more efficient than using categorical age-smoking criteria, such as the US Preventive Services Task Force (USPSTF) criteria. This study prospectively compared the effectiveness of the USPSTF2013 and PLCOm2012 model eligibility criteria. METHODS: In this prospective cohort study, participants from the International Lung Screening Trial (ILST), aged 55-80 years, who were current or former smokers (ie, had ≥30 pack-years smoking history or ≤15 quit-years since last permanently quitting), and who met USPSTF2013 criteria or a PLCOm2012 risk threshold of at least 1·51% within 6 years of screening, were recruited from nine screening sites in Canada, Australia, Hong Kong, and the UK. After enrolment, patients were assessed with the USPSTF2013 criteria and the PLCOm2012 risk model with a threshold of at least 1·70% at 6 years. Data were collected locally and centralised. Main outcomes were the comparison of lung cancer detection rates and cumulative life expectancies in patients with lung cancer between USPSTF2013 criteria and the PLCOm2012 model. In this Article, we present data from an interim analysis. To estimate the incidence of lung cancers in individuals who were USPSTF2013-negative and had PLCOm2012 of less than 1·51% at 6 years, ever-smokers in the Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO) who met these criteria and their lung cancer incidence were applied to the ILST sample size for the mean follow-up occurring in the ILST. This trial is registered at ClinicalTrials.gov, NCT02871856. Study enrolment is almost complete. FINDINGS: Between June 17, 2015, and Dec 29, 2020, 5819 participants from the International Lung Screening Trial (ILST) were enrolled on the basis of meeting USPSTF2013 criteria or the PLCOm2012 risk threshold of at least 1·51% at 6 years. The same number of individuals was selected for the PLCOm2012 model as for the USPSTF2013 criteria (4540 [78%] of 5819). After a mean follow-up of 2·3 years (SD 1·0), 135 lung cancers occurred in 4540 USPSTF2013-positive participants and 162 in 4540 participants included in the PLCOm2012 of at least 1·70% at 6 years group (cancer sensitivity difference 15·8%, 95% CI 10·7-22·1%; absolute odds ratio 4·00, 95% CI 1·89-9·44; p<0·0001). Compared to USPSTF2013-positive individuals, PLCOm2012-selected participants were older (mean age 65·7 years [SD 5·9] vs 63·3 years [5·7]; p<0·0001), had more comorbidities (median 2 [IQR 1-3] vs 1 [1-2]; p<0·0001), and shorter life expectancy (13·9 years [95% CI 12·8-14·9] vs 14·8 [13·6-16·0] years). Model-based difference in cumulative life expectancies for those diagnosed with lung cancer were higher in those who had PLCOm2012 risk of at least 1·70% at 6 years than individuals who were USPSTF2013-positive (2248·6 years [95% CI 2089·6-2425·9] vs 2000·7 years [1841·2-2160·3]; difference 247·9 years, p=0·015). INTERPRETATION: PLCOm2012 appears to be more efficient than the USPSTF2013 criteria for selecting individuals to enrol into lung cancer screening programmes and should be used for identifying high-risk individuals who benefit from the inclusion in these programmes. FUNDING: Terry Fox Research Institute, The UBC-VGH Hospital Foundation and the BC Cancer Foundation, the Alberta Cancer Foundation, the Australian National Health and Medical Research Council, Cancer Research UK and a consortium of funders, and the Roy Castle Lung Cancer Foundation for the UK Lung Screen Uptake Trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00590-8

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 167

Metadata

Authors
Tammemägi, M. C., Ruparel, M., Tremblay, A., Myers, R., Mayo, J., Yee, J., Atkar-Khattra, S., Yuan, R., Cressman, S., English, J., Bedard, E., MacEachern, P., Burrowes, P., Quaife, S. L., Marshall, H., Yang, I., Bowman, R., Passmore, L., McWilliams, A., Brims, F., Lim, K. P., Mo, L., Melsom, S., Saffar, B., Teh, M., Sheehan, R., Kuok, Y., Manser, R., Irving, L., Steinfort, D., McCusker, M., Pascoe, D., Fogarty, P., Stone, E., Lam, D. C. L., Ng, M.-Y., Vardhanabhuti, V., Berg, C. D., Hung, R. J., Janes, S. M., Fong, K., & Lam, S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2022-01
Volume
23
Issue
1
Pages
138-148
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4200116461
Cited by
167
References
3
FWCI
13.47
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00590-8
The paper
Tammemägi, M. C., Ruparel, M., Tremblay, A., Myers, R., Mayo, J., Yee, J., Atkar-Khattra, S., Yuan, R., Cressman, S., English, J., Bedard, E., MacEachern, P., Burrowes, P., Quaife, S. L., Marshall, H., Yang, I., Bowman, R., Passmore, L., McWilliams, A., . . . Lam, S. (2022). USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00590-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.